- Sage Therapeutics (NASDAQ:SAGE) reports that it expects to announce topline data from a Phase 2 clinical trial evaluating SAGE-217 in women with postpartum depression (PPD) in Q4.
-
SAGE-217, a neuroactive steroid, is next-generation GABA modulator. The GABA system, the major inhibitory signaling pathway in the brain and central nervous system (CNS), plays a key role in regulating CNS function.
- It also expects the $575M proceeds from its planned stock offering, along with cash on hand and expected sales from brexolone IV, to be sufficient to fund operations into 2020.
- Previously: Sage Therapeutics launches mid-stage study of SAGE-217 in PPD (Dec. 19, 2016)